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Abstract
 OBJECTIVE—The purpose of this study was to examine the risk of birth defects in relation to 
diabetes mellitus and the lack of use of periconceptional vitamins or supplements that contain folic 
acid.
 STUDY DESIGN—The National Birth Defects Prevention Study (1997-2004) is a multicenter, 
population-based case-control study of birth defects (14,721 cases and 5437 control infants). Cases 
were categorized into 18 types of heart defects and 26 noncardiac birth defects. We estimated odds 
ratios for independent and joint effects of preexisting diabetes mellitus and a lack of 
periconceptional use of vitamins or supplements that contain folic acid.
 RESULTS—The pattern of odds ratios suggested an increased risk of defects that are 
associated with diabetes mellitus in the absence vs the presence of the periconceptional use of 
vitamins or supplements that contain folic acid.
 CONCLUSION—The lack of periconceptional use of vitamins or supplements that contain 
folic acid may be associated with an excess risk for birth defects due to diabetes mellitus.
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Offspring of mothers with preexisting diabetes mellitus (ie, type 1 or 2) have a 2- to 4-fold 
increased risk for a wide spectrum of birth defects.1-3 Human studies have shown that 
hyperglycemia during organogenesis is associated with an increased risk for birth defects 
and that this risk correlates directly with maternal glucose levels.4-7 However, animal studies 
have suggested a complex pathogenetic process that also involves excess concentrations of 
other biochemical abnormalities that are associated with hyperglycemia (eg, elevated 
triglycerides, branched-chain amino acids, β-hydroxy-butyrate, somatomedin inhibitors, and 
reactive oxygen species) as potential cofactors in diabetic embryopathy.8-10
Multidisciplinary preconception care programs that are focused on glucose monitoring and 
control during the periconceptional period have been associated with a reduction in 
prevalence of birth defects among offspring of pregnancies that were complicated by 
preexisting diabetes mellitus.11,12 However, continuing occurrence of birth defects among 
offspring of pregnancies that are complicated by preexisting diabetes mellitus1,2,13 
underscores ongoing challenges that face prevention efforts. One challenge is that 
approximately one-third of reproductive aged women with preexisting diabetes mellitus are 
undiagnosed.14 Furthermore, >60% of women with preexisting diabetes mellitus have 
unplanned pregnancies, lack access to preconception care, or might find it difficult to 
comply with prescribed glycemic control regimens.15-17
Holding some promise for prevention efforts are reports from animal studies that suggest 
that high doses of certain antioxidants (eg, vitamins C and E),18,19 fatty acids (eg, lipoic acid 
and arachidonic acid),20,21 and possibly folic acid22,23 can reduce the risk for birth defects 
among pregnancies that are complicated by diabetes mellitus. Human studies have 
demonstrated that maternal periconceptional use of folic acid or multivitamin supplements 
that contain folic acid reduces the risk for neural tube defects.24,25 However, evidence of 
similar risk reduction for other defects has been less consistent.26,27
Because offspring of women with preexisting diabetes mellitus are at increased risk for 
neural tube defects, the American Diabetes Association supports the US Public Health 
Service recommendation that women who are capable of becoming pregnant consume 400 
μg of folic acid daily from all sources and further stipulates that, during periconceptional and 
prenatal periods, women with preexisting diabetes mellitus increase their folic acid intake to 
600 μg daily through supplements or fortified food sources.12,28 However, data on efficacy 
of periconceptional folic acid in-take regarding the risk of birth defects among women with 
preexisting diabetes mellitus are limited.29
We used the National Birth Defects Prevention Study (NBDPS), which is a population-
based, case-control study of birth defects, to examine the independent and joint effects of 
preexisting diabetes mellitus and the absence of periconceptional intake of vitamins or 
supplements that contain folic acid on the occurrence of birth defects.
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 Materials and Methods
 Study population
The NBDPS is an ongoing study that is based on birth defects surveillance systems in the 
following states: Arkansas, California, Georgia/Centers for Disease Control and Prevention, 
Iowa, Massachusetts, New Jersey (through 2002), New York, North Carolina (beginning 
2003), Texas, and Utah (beginning 2003).30 Case infants who were selected for the study 
had at least 1 of >30 eligible birth defects and were liveborn, stillborn, or electively 
terminated. Case records were reviewed systematically by clinical geneticists to exclude 
case infants with recognized or strongly suspected single-gene conditions or chromosomal 
abnormalities. Control infants were liveborn infants without birth defects who were selected 
randomly either from birth certificates or hospital birth records. Mothers were interviewed in 
either English or Spanish by telephone 6 weeks to 24 months after the estimated date of 
delivery with the use of a computer-based questionnaire. Interviewers obtained information 
on maternal demographic characteristics, exposures (eg, nutritional, behavioral, or 
occupational), and medication use both before and during pregnancy. Interview participation 
rates were 70% among mothers of case infants and 67% among mothers of control infants. 
The NBDPS was approved by the institutional review boards of the Centers for Disease 
Control and Prevention and the participating study centers.
Clinical information on case infants was reviewed by a team of clinical geneticists and 
clinicians with expertise in pediatric cardiology.31,32 Case infants were classified as having 
an isolated birth defect if they had (a) 1 major birth defect only; (b) 1 major birth defect and 
≥1 minor birth defects; (c) ≥1 major birth defects that affect 1 organ system only; or (d) 1 
major birth defect with a well-described sequence of related defects and no major unrelated 
birth defects. Case infants were classified as having multiple birth defects if they had ≥2 
major unrelated defects in different organ systems.31 For case infants with a congenital heart 
defect (CHD), an additional layer of classification was used to denote “simple” cases as 
anatomically discrete or having a well-recognized single malformation (eg, hypoplastic left 
heart syndrome or tetralogy of Fallot).32
 Definitions of exposures and covariates
All information was self-reported during the maternal telephone interviews. Mothers 
reported whether a physician had diagnosed them previously with preexisting diabetes 
mellitus or gestational diabetes mellitus. Based on such reports, we classified case and 
control infants into 1 of 4 mutually exclusive categories: (1) infant of a mother with 
preexisting diabetes mellitus, if the mother reported having been diagnosed with type 1 or 
type 2 diabetes mellitus before the estimated date of conception of the index infant; (2) 
infant of a mother with gestational diabetes mellitus, if the mother reported having been 
diagnosed with gestational diabetes mellitus during the index pregnancy; (3) infant of a 
nondiabetic mother, if the mother reported never having been diagnosed with any type of 
diabetes mellitus; and (4) unknown, if the response was missing or inconstant (maternal 
report of preexisting diabetes mellitus diagnosed during the index pregnancy). The current 
analyses covered only infants of mothers who had been classified into categories 1 and 3.
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Mothers were asked about their use of a multivitamin, prenatal vitamin, or single-component 
vitamin, including information on the product brand used, start and stop dates (and/or 
duration of use), and frequency of use. If exact dates of use were unknown, mothers could 
report less specific information, such as a pregnancy month (eg, first month of pregnancy) or 
time of year (eg, beginning of the year), which was converted into dates to determine the 
timing of the use in relation to the pregnancy. NBDPS investigators determined whether the 
specific product that was reported contained folic acid.33 Periconceptional users of vitamins 
or supplements that contain folic acid were identified as mothers who reported any use 
during the month before conception or during the first 3 months of pregnancy. Those who 
reported no use during the entire time period from 1 month before conception through the 
end of the first trimester were considered nonusers. Mothers with an unknown intake, those 
who began in-take after the end of the first trimester, or those who began (and ended) intake 
before the start of the month before conception were excluded from these analyses.
Several covariates were considered potential confounders. Self-reported prepregnancy height 
and weight were converted to metric units and maternal body mass index was calculated as 
weight in kilograms divided by height in square meters (kg/m2). Four body mass index 
groups were formed: (1) underweight (<18.5 kg/m2), (2) normal weight (18.5-24.9 kg/m2), 
(3) overweight (25.0-29.9 kg/m2), and (4) obese (≥30.0 kg/m2).34 Additional variables 
included maternal age (<20, 20-24, 25-29, 30-34, and ≥35 years), maternal race or ethnicity 
(non-Hispanic white, non-Hispanic black or African American, Hispanic, and other race or 
ethnicity), timing of entry into prenatal care (≤10 weeks gestation vs later), annual 
household income (≥$40,000 vs less), and parity (first vs subsequent livebirth).
 Exclusions
Case and control infants who were delivered during the period from October 1, 1997, 
through December 31, 2004, were eligible for this study. We restricted the analysis to case 
and control mothers with preexisting diabetes mellitus (type 1 or type 2) with a known date 
of diagnosis (month and year) before the index pregnancy and mothers with no diabetes 
mellitus of any type. Of the 16,419 case mothers and 5958 control mothers who participated 
in the NBDPS, 1313 case and 386 control mothers with gestational diabetes mellitus or with 
unknown or inconsistent diabetes mellitus status were excluded, as were 441 case and 147 
control mothers who were neither definitive users nor nonusers of vitamins or supplements 
that contain folic acid during the period of 1 month before pregnancy through the third 
month of pregnancy. Because 56 case and 12 control mothers met both exclusion criteria, the 
final analyses comprised 14,721 case mothers and 5437 control mothers. Control infants 
who were included in the analyses of hypospadias were restricted to male infants only.
 Statistical analysis
We conducted multiple logistic regressions using the covariates that were described 
previously to estimate relative risks with adjusted odds ratios and 95% confidence intervals. 
We evaluated the independent and joint effects of preexisting diabetes mellitus and the 
absence of the periconceptional intake of vitamins or supplements that contain folic acid by 
comparing the risk for birth defects among 4 mutually exclusive groupings of mothers: (1) 
mothers without diabetes mellitus with periconceptional intake of vitamins or supplements 
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that contain folic acid (reference group), (2) mothers without diabetes mellitus with no 
periconceptional in-take of vitamins (the “independent” effect of no periconceptional 
intake), (3) mothers with preexisting diabetes mellitus with periconceptional intake of 
vitamins that contain folic acid (the “independent” effect of preexisting diabetes mellitus), 
and (4) mothers with preexisting diabetes mellitus with no periconceptional intake of 
vitamins (joint effect). To assess whether there was an interaction between diabetes mellitus 
and a lack of intake of vitamins that contain folic acid that departed from additivity of 
effects, we calculated the relative excess risk due to interaction (RERI) and its 95% 
confidence interval. The confidence intervals were calculated based on Taylor expansions of 
the variances and covariances from the multiple logistic regression models. A spreadsheet 
(Microsoft Excel, version 1997-2003; Microsoft Corporation, Redmond, WA) that was 
developed by Andersson et al35 and available at www.epinet.se facilitated these calculations. 
RERI estimates greater than zero suggested superadditive effects, although estimates equal 
to zero suggested additive effects only.
We assessed the sensitivity of our results to certain exclusions and definitions by looking at 
changes in estimates associated with (1) the exclusion of multiple gestations and a first-
degree family history of birth defects (2 strong, but uncommon, risk factors), (2) changes in 
the definition of periconceptional intake of vitamins or supplements that contain folic acid 
(ie, changes in the gestational months of periconceptional use), and (3) the restriction of the 
analyses to cases of isolated birth defects only. All analyses were conducted with SAS 
software (version 9.2; SAS Institute, Inc, Cary, NC).
 Results
The prevalence of preexisting diabetes mellitus was 0.5% among control mothers and 2.4% 
among case mothers. Reported use of vitamins that contain folic acid in the periconceptional 
period (ie, in the month before conception or the first 3 months of pregnancy) was similar in 
both groups, approximately 87%. Fifty-seven case mothers (0.4%) and only 2 control 
mothers were in the hypothesized group at highest risk (those with preexisting diabetes 
mellitus and without periconceptional intake of vitamins that contain folic acid). Case and 
control mothers differed in this joint distribution. They also differed with respect to body 
mass index, education, parity, household income, and timing of entry into prenatal care 
(Table 1).
Tables 2 and 3 show the independent and joint effect estimates of the association between 
maternal preexisting diabetes mellitus and the lack of periconceptional intake of vitamins or 
supplements that contain folic acid and the occurrence of CHDs and noncardiac birth 
defects, respectively. RERI could be calculated for 9 of 13 specific types of CHDs. For 8 of 
these 9 specific types of CHDs (Table 2), there was a suggestion of superadditive effects 
(RERI estimate, >0); for any CHD, there was an increased point estimate for the effect of 
preexisting diabetes mellitus in the absence of the periconceptional intake of vitamins that 
contain folic acid compared with the effect of preexisting diabetes mellitus in the presence 
of vitamin intake that contains folic acid (eg, any CHD: No, No = 1.13; Yes, Yes = 5.51; 
Yes, No = 13.35). For 4 CHD subtypes, there were no case infants in the highest risk group; 
therefore, the RERI could not be calculated. Of the 8 specific CHD subtypes with RERI 
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estimates of >0, 6 subtypes had estimates of >2.0 and a point estimate for the joint effect of 
preexisting diabetes mellitus in the absence of periconceptional intake of vitamins that 
contain folic acid approximately ≥2 times that of the effect of preexisting diabetes mellitus 
in the presence of periconceptional intake of vitamins. However, the RERI estimates were 
imprecise and did not reach statistical significance for any of the types of CHDs or CHD 
groups.
A similar pattern was seen for noncardiac birth defects (Table 3). Independent and joint 
effects could be calculated for 13 of 21 specific types of these birth defects, for 9 of which 
there were suggestive synergistic effects (RERI, >0). The analyses for 8 of these 13 types of 
birth defects yielded RERI estimates of >2.0 and an estimate of the odds of a case for the 
joint effect of preexisting diabetes mellitus with no periconceptional intake of vitamins that 
contain folic acid approximately ≥2 times that of the odds of a case for preexisting diabetes 
mellitus with periconceptional intake of vitamins that contain folic acid. A negative RERI 
was obtained for only 1 type of birth defect, anotia-microtia. Again, however, the RERI 
estimates were imprecise and not statistically significant.
Sensitivity analyses that restricted the study sample to singleton births (case infants, 94%; 
control infants, 97%) or to case infants without a first-degree family history of the birth 
defect of interest (94-100% of each case group) and control infants without a first-degree 
family history of any birth defect (98% of control infants) did not yield meaningfully 
different results. Similarly, the restriction of the analyses to isolated case infants (or infants 
with simple, isolated CHD) or the use of a more conservative definition of supplement use (1 
month before to 1 month after the date of conception) did not change the results appreciably 
but increased the confidence intervals considerably and led to less distinction in effect 
estimates between the exposure groups (data not shown).
 Comment
We found evidence for an association between preexisting diabetes mellitus and increased 
risk for birth defects despite the use of vitamins or supplements that contain folic acid. Our 
findings for specific birth defects were limited by small numbers of case mothers who were 
exposed jointly to preexisting diabetes mellitus and no periconceptional use of vitamins or 
supplements that contain folic acid. However, there was evidence to suggest that the 
offspring of mothers with preexisting diabetes mellitus and no periconceptional use of 
vitamins or supplements that contain folic acid experienced at least a nonstatistically 
significant 2-fold greater risk for birth defects when compared with the offspring of mothers 
with preexisting diabetes mellitus who reported the periconceptional use of vitamins or 
supplements that contain folic acid.
Strengths of this study included the large representative sample and standardized procedures 
for case definition and classification of birth defects. The control population was a 
representative sample of infants without defects from the delivery cohorts that gave rise to 
the infants with birth defects.30,36 Case infants were identified by population-based 
surveillance systems that used multiple sources for ascertainment. In addition, interview 
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participation rates were comparable for case and control mothers, and our findings changed 
little with adjustment for potential confounders.
Our classification of diabetes mellitus that was based on maternal reports of diagnosed 
diabetes mellitus was similar to that used in previous population-based, case-control studies 
of birth defects.1,37 Because self-reports of diabetes mellitus tend to have <100% 
sensitivity,38,39 the underreporting of diabetes mellitus by women with a previous diagnosis 
of diabetes mellitus probably resulted in a lower prevalence of preexisting diabetes mellitus 
in pregnancy among our study control women (0.5%) than that reported among pregnant 
women in the general population (0.75%), where the diagnosis of preexisting diabetes 
mellitus was based on hospital discharge data.40 Because some women with diabetes 
mellitus might have been undiagnosed, it is possible that a fraction of the women who 
reported having no diabetes mellitus actually might have had undiagnosed type 2 diabetes 
mellitus, which would result in further exposure misclassification. Because there was no 
reason to believe that the resultant misclassification of diabetes mellitus status occurred 
differently for case and control mothers, the net effect of such misclassification probably 
was of an attenuation of associations of diabetes mellitus with birth defects.
The low prevalence of reported preexisting diabetes mellitus limited our ability to obtain 
reliable estimates for the joint effect of preexisting diabetes mellitus and the lack of use of 
vitamins or supplements that contain folic acid on the risk for birth defects. For 
approximately 33% of the specific types of birth defects (12/35 defects), we were not able to 
obtain an estimate of a joint effect because of a lack of case mothers in this exposure 
category. However, a consistent pattern of a greater odds ratio for the joint effect of 
preexisting diabetes mellitus and no periconceptional vitamin or supplement use other than 
for the independent effect of preexisting diabetes mellitus (in the presence of 
periconceptional vitamin or supplement use) for approximately 75% of the specific types of 
birth defects (17/23 defects) examined is noteworthy and warrants corroboration.
Our assessment of the independent and joint effects of diabetes mellitus and the lack of use 
of supplements that contain folic acid was based on the assumption that the level of 
glycemic control was similar across groups of women with diabetes mellitus, regardless of 
supplement use. However, it is likely that women with diabetes mellitus who used 
supplements also planned their pregnancies and therefore may have had better glycemic 
control before and early in pregnancy than women with diabetes mellitus who did not use 
supplements and who may not have planned their pregnancies. Because the timely institution 
of intensive glycemic control for pregnant women with insulin-dependent diabetes mellitus 
has been associated with the rates of birth defects that are similar to those observed among 
pregnant women who did not have diabetes mellitus,4,6,41 it is possible that the apparent 
synergistic effects of diabetes mellitus and the lack of supplement use may reflect 
underlying differences in pregnancy planning and diabetes mellitus control rather than an 
effect of a lack of supplement use per se. This possibility remains an important 
consideration, given that >50% of women with diabetes mellitus do not plan their 
pregnancies and that we did not have information on the level of glycemic control among 
case and control mothers.
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The validity of self-reported supplement intake is likely to be high,42,43 particularly with 
regard to folic acid content, given the predominant intake of prenatal supplements that have 
relatively standard folic acid content. The extent of error in the reported dates of intake, 
however, is unknown. Our definition of supplement intake (ie, any use during the month 
before conception or during the first 3 months of pregnancy) was more inclusive than the 
ones that were used in other studies and may explain the higher prevalence of supplement 
use that was observed in our study. We chose a more inclusive definition of supplement use 
to provide more precise point estimates for the associations of interest, albeit at the risk of 
being biased towards the null.
Our finding of no consistent association between neural tube defects and maternal 
supplement use among the off-spring of women without preexisting diabetes mellitus 
differed from observations in studies that were conducted before the era of folic acid 
fortification (ie, 1998). Those studies were generally consistent regarding a protective effect 
of the periconceptional use of folic acid against neural tube defects and formed the basis for 
the US Public Health Service recommendation that women who were capable of becoming 
pregnant should consume 400 μg of folic acid each day.24,25,28 Our findings on neural tube 
defects and supplement use, however, were consistent with a report of recent decreases in 
the prevalence of low serum (<3 ng/mL) and red blood cell (<140 ng/mL) folate levels 
among women of childbearing age in the United States (20.6-0.6% and 37.6-5.5%, 
respectively, from 1988-1994 to 2003-2004).44 Another possibility that could explain the 
lack of a protective effect of supplement use against neural tube defects is that some 
pregnancies that were affected by neural tube defects in the study birth cohort were 
terminated without being enrolled in the study.
Our finding that offspring of women with preexisting diabetes mellitus who reported no 
periconceptional use of vitamins or supplements that contain folic acid appeared to be at 
greater risk for birth defects than the offspring of women with preexisting diabetes mellitus 
who had reported use of vitamins or supplements that contain folic acid is consistent with 
that of a previous epidemiologic study.29 This observation also is consistent with results 
from animal studies among pregnancies that were complicated by diabetes mellitus and 
showed that the administration of high doses of the antioxidant vitamins E and C,18,45 
certain fatty acids,20,21,46 or folic acid can prevent diabetic embryopathy.22,23,47 In our 
study, we had adequate information to classify supplements that contain folic acid and those 
that contain vitamin E or C. However, we had no information on the concentration of 
micronutrients or on the dose that was taken. Furthermore, we found a high concordance 
between the intake of supplements that contain folic acid and supplements that contain 
vitamins E and C, which made it difficult to evaluate the independent and joint effects of 
intake of these different types of micronutrients. As in a previous study, we were not able to 
account for potential confounding by the level of glycemic control, which still remains to be 
another possible explanation for our findings.
The risk of birth defects among women with preexisting diabetes mellitus remains very high. 
Prevention of the excess of birth defects for children who are born to women with 
preexisting diabetes mellitus would make a marked improvement in the health of children. 
So far, we have made little progress in reaching this goal. The strongest evidence we have, 
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and we have only observational data, is that good glucose control before and early in 
pregnancy is associated with a lower risk of birth defects. Until there is better evidence, we 
should seek to improve glucose control of all women of reproductive age who have 
preexisting diabetes mellitus, especially among those who are planning a pregnancy. All 
women of reproductive age should be encouraged to consume enough folic acid. In countries 
such as Europe where there is no required folic acid fortification, all women of reproductive 
age should be encouraged to consume vitamin supplements that contain folic acid because it 
is known from randomized controlled trials that such consumption will prevent spina bifida 
and anencephaly. In countries such as the United States and Canada where there is 
fortification, there is uncertainty about what additional prevention may occur from 
consuming a multivitamin with folic acid. Our data are consistent with the idea (but it is far 
from established) that such consumption may decrease the risk of certain birth defects 
among the offspring of women with preexisting diabetes mellitus.
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TABLE 1
Characteristics of mothers of control and case infants: National Birth Defects Prevention Study, 1997-2004
Control infants (n = 5437) Case infants (n = 14,721)
Characteristic n % n % P value
Preexisting diabetes mellitus 29 0.5 346 2.4 < .0001
Periconceptional
a
 intake of vitamins or supplements that contain folic 
acid
4764 87.6 12,791 86.9 .17
Joint distribution of preexisting diabetes mellitus and periconceptional
a 
intake of vitamins or supplements that contain folic acid
< .0001
    No diabetes mellitus, yes periconceptional intake 4737 87.1 12,502 84.9
    No diabetes mellitus, no periconceptional intake 671 12.3 1873 12.7
    Yes preexisting diabetes mellitus, yes periconceptional intake 27 0.5 289 2.0
    Yes preexisting diabetes mellitus, no periconceptional intake 2 0.0 57 0.4
Body mass index, kg/m2 .002
    <18.5 306 5.6 849 5.8
    18.5 ≤25.0 2993 55.0 7760 52.7
    25.0 ≤30.0 1142 21.0 3152 21.4
    ≥30.0 788 14.5 2420 16.4
    Missing 208 3.8 540 3.7
Age, y .71
    <20 616 11.3 1730 11.8
    20-24 1249 23.0 3482 23.7
    25-29 1433 26.4 3744 25.4
    30-34 1398 25.7 3615 24.6
    ≥35 741 13.6 2150 14.6
Education .002
    <High school 890 16.4 2575 17.5
    High school 1329 24.4 3820 25.9
    >High school 3166 58.2 8202 55.7
    Missing 124 2.3 52 0.4
Race and ethnicity .65
    Non-Hispanic white 3288 60.5 8952 60.8
    Non-Hispanic black or African American 623 11.5 1517 10.3
    Hispanic 1180 21.7 3290 22.3
    Other 329 6.1 920 6.2
    Missing 17 0.3 42 0.3
Parity < .0001
    First livebirth 2235 41.1 6567 44.6
    Second or subsequent livebirth 3201 58.9 8148 55.3
    Missing 1 0 6 0
Multip1e gestation pregnancy 155 2.9 911 6.2 < .0001
Household income ≥$40,000/y
b 2122 39.0 5596 38.0 .009
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Control infants (n = 5437) Case infants (n = 14,721)
Characteristic n % n % P value
Entry into prenatal care at or before 10 weeks gestation
c 3614 66.5 9975 67.8 .04
Correa. Lack of folic acid supplements and diabetes mellitus–associated birth defects. Am J Obstet Gynecol 2012.
a
Any intake in the month before conception or during the first 3 months of pregnancy
b
Household income was missing for 3% of control infants and 6.5% of case infants
c
Prenatal care information was missing for 0.3% of control infants and 1% of case infants.
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TABLE 2
Independent and joint effect estimates for selected congenital heart defects: National Birth Defects Prevention 
Study, 1997-2004















Any congenital heart defect No Yes 5206:4737 Reference 7.71 (–11.55 to 
26.97)
No No 773:671 1.13 (0.99–1.30)
Yes Yes 180:27 5.51 (3.60–8.42)
Yes No 35:2 13.35 (3.18–55.96)
Heterotaxia No Yes 128:4737 Reference Not calculated
No No 34:671 1.25 (0.76–2.05)
Yes Yes 9:27 11.94 (5.06–28.20)
Yes No 0:2 Not calculated
Any conotruncal defect No Yes 1034:4737 Reference 5.73 (–14.71 to 
26.18)
No No 140:671 1.09 (0.86–1.38)
Yes Yes 41:27 6.41 (3.82–10.77)
Yes No 7:2 12.23 (2.3–63.93)
    Truncus arteriosus No Yes 43:4737 Reference 28.89 (–114.00 
to 171.78)
No No 6:671 1.22 (0.40–3.69)
Yes Yes 6:27 24.93 (8.99–69.13)
Yes No 2:2 54.04 (3.85–759.21)
    Tetralogy of Fallot No Yes 460:4737 Reference 11.91 (–18.19 
to 42.02)
No No 59:671 0.99 (0.70–1.41)
Yes Yes 16:27 4.57 (2.28–9.16)
Yes No 3:2 16.48 (2.67–101.80)
    D-transposition of the great 
arteries
No Yes 320:4737 Reference 0.81 (–18.02 to 
19.65)
No No 50:671 1.51 (1.05–2.17)
Yes Yes 9:27 6.16 (2.80–13.56)
Yes No 2:2 7.49 (0.65–85.72)
Atrioventricular septal defect No Yes 122:4737 Reference 42.49 (–71.02 
to 156.00)
No No 18:671 1.26 (0.69–2.29)
Yes Yes 8:27 12.24 (5.17–28.93)
Yes No 2:2 54.98 (7.00–432.12)
Total anomalous pulmonary 
venous return
No Yes 122:4737 Reference Not calculated
No No 16:671 0.94 (0.50–1.76)
Yes Yes 3:27 4.82 (1.40–16.64)
Yes No 0:2 Not calculated
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Any left ventricular outflow 
tract obstruction defect
No Yes 840:4737 Reference 1.59 (–9.34 to 
12.51)
No No 84:671 0.79 (0.59–1.06)
Yes Yes 19:27 4.01 (2.15–7.48)
Yes No 2:2 5.39 (0.75–38.93)
    Hypoplastic left heart 
syndrome
No Yes 246:4737 Reference Not calculated
No No 21:671 0.58 (0.32–1.05)
Yes Yes 6:27 3.42 (1.27–9.22)
Yes No 0:2 Not calculated
    Coarctation of the aorta No Yes 434:4737 Reference 4.42 (–13.18 to 
22.03)
No No 52:671 0.96 (0.67–1.38)
Yes Yes 10:27 4.32 (2.02–9.24)
Yes No 2:2 8.70 (1.19–63.88)
    Aortic stenosis No Yes 191:4737 Reference Not calculated
No No 13:671 0.58 (0.30–1.13)
Yes Yes 5:27 5.35 (1.95–14.68)
Yes No 0:2 Not calculated
Any right ventricular outflow 
tract obstruction defect
No Yes 726:4737 Reference 4.58 (–9.47 to 
18.63)
No No 112:671 1.28 (0.99–1.65)
Yes Yes 15:27 2.83 (1.42–5.62)
Yes No 3:2 7.69 (1.25–47.18)
    Pulmonary atresia No Yes 107:4737 Reference 12.38 (–26.41 
to 51.61)
No No 14:671 1.06 (0.56–2.00)
Yes Yes 2:27 3.01 (0.68–13.25)
Yes No 1:2 15.45 (1.26–189.12)
    Pulmonary valve stenosis
d No Yes 569:4390 Reference 2.43 (–9.61 to 
14.47)
No No 86:599 1.29 (0.97–1.72)
Yes Yes 12:24 3.22 (1.53–6.78)
Yes No 2:2 5.94 (0.81–43.52)
Ventricular septal defect: 
perimembranous
No Yes 928:4737 Reference 5.35 (–12.16 to 
22.86)
No No 152:671 1.25 (0.99–1.57)
Yes Yes 28:27 4.43 (2.51–7.82)
Yes No 5:2 10.03 (1.77–56.66)
Atrial septal defect: secundum 
or not otherwise specified
No Yes 1274:4737 Reference 9.45 (–15.70 to 
34.59)
No No 227:671 1.25 (1.03–1.53)
Yes Yes 56:27 6.76 (4.16–10.98)
Yes No 11:2 16.46 (3.61–75.07)
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CI, confidence interval.
Correa. Lack of folic acid supplements and diabetes mellitus–associated birth defects. Am J Obstet Gynecol 2012.
a
For maternal diabetes mellitus: Yes = preexisting diabetes mellitus; No = no diabetes mellitus of any type
b
For use of vitamins: Yes = any use from the period of 1 month before pregnancy through the third month of pregnancy of a vitamin or supplement 
that contains folic acid; No = no use during the month before conception and the first 3 months of pregnancy of a vitamin or supplement that 
containsfolic acid
c
Adjusted for maternal age, race, and ethnicity, entry into prenatal care, prepregnancy body mass index, parity, and household income
d
Note the different number of control infants for pulmonary valve stenosis because of limited ascertainment in California.
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TABLE 3
Independent and joint effect estimates for selected noncardiac birth defects: National Birth Defects Prevention 
Study, 1997–2004















Any birth defect No Yes 12502:4737 Reference 5.92 (–7.96 to 
19.79)
No No 1873:671 1.12 (1.00–1.26)
Yes Yes 289:27 3.27 (2.46–5.63)
Yes No 57:2 9.77 (2.38–40.12)
Any neural tube defect No Yes 787:4737 Reference 6.65 (–7.83 to 
21.14)
No No 138:671 1.08 (0.84–1.38)
Yes Yes 10:27 1.66 (0.73–3.74)
Yes No 4:2 8.39 (1.50–46.89)
    Anencephaly No Yes 233:4737 Reference 29.72 (–28.54 
to 87.99)
No No 32:671 1.03 (0.65–1.63)
Yes Yes 2:27 1.80 (0.42–7.81)
Yes No 3:2 31.56 (4.98–199.94)
    Spina bifida No Yes 470:4737 Reference 0.69 (–5.25 to 
6.64)
No No 84:671 1.02 (0.75–1.38)
Yes Yes 5:27 1.66 (0.62–4.42)
Yes No 1:2 2.37 (0.21–26.68)
    Encephalocele No Yes 84:4737 Reference Not calculated
No No 22:671 1.60 (0.88–2.92)
Yes Yes 3:27 1.84 (0.24–14.13)
Yes No 0:2 Not calculated
Hydrocephaly No Yes 204:4737 Reference 20.03 (–26.68 
to 66.74)
No No 34:671 0.97 (0.60–1.55)
Yes Yes 8:27 5.63 (2.36–13.41)
Yes No 3:2 25.63 (4.16–158.02)
Holoprosencephaly No Yes 48:4737 Reference Not calculated
No No 13:671 1.52 (0.69–3.39)
Yes Yes 2:27 9.06 (1.97–41.77)
Yes No 0:2 Not calculated
Anotia-Microtia No Yes 263:4737 Reference –1.51 (–16.30 
to 13.28)
No No 53:671 1.01 (0.69–1.48)
Yes Yes 13:27 7.07 (3.27–15.28)
Yes No 1:2 5.57 (0.46–66.97)
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Choanal atresia No Yes 70:4737 Reference Not calculated
No No 9:671 1.27 (0.55–2.95)
Yes Yes 0:27 Not calculated
Yes No 1:2 45.96 (3.54–597.50)
Any oral cleft
d No Yes 1835:4613 Reference 11.36 (–9.78 
to 32.51)
No No 315:665 1.30 (1.09–1.55)
Yes Yes 23:27 2.17 (1.20–3.93)
Yes No 11:2 13.84 (3.01–63.68)
    Cleft palate
d No Yes 642:4613 Reference 0.50 (–8.14 to 
8.24)
No No 103:665 1.54 (1.18–2.01)
Yes Yes 10:27 2.68 (1.26–5.68)
Yes No 1:2 3.27 (0.29-37.13)
    Cleft lip with or without cleft 
palate
d
No Yes 1193:4613 Reference 17.30 (–12.59 
to 47.19)
No No 212:665 1.20 (0.98–1.47)
Yes Yes 13:27 1.83 (0.88–3.77)
Yes No 10:2 19.33 (4.12–90.69)
Esophageal atresia No Yes 311:4737 Reference Not calculated
No No 38:671 1.03 (0.66–1.59)
Yes Yes 6:27 3.25 (1.28–8.24)
Yes No 0:2 Not calculated
Ileal, jejunal, and multiple small 
intestinal atresias
No Yes 182:4737 Reference Not calculated
No No 34:671 1.32 (0.85–2.04)
Yes Yes 0:27 Not calculated
Yes No 0:2 Not calculated
Anorecal atresia No Yes 422:4737 Reference 23.87 (–23.81 
to 71.54)
No No 72:671 1.42 (1.03–1.95)
Yes Yes 12:27 4.41 (2.08–9.38)
Yes No 5:2 28.70 (5.46–150.97)
Biliary atresia No Yes 73:4737 Reference 45.05 (–75.08 
to 165.19)
No No 11:671 1.13 (0.55–2.33)
Yes Yes 1:27 2.56 (0.33–19.53)
Yes No 1:2 47.74 (3.85–592.05)
Hypospadias
d No Yes 966:2374 Reference 1.51 (–9.19 to 
12.22)
No No 76:338 0.84 (0.60–1.15)
Yes Yes 17:16 2.44 (1.14–5.20)
Yes No 1:1 3.78 (0.23–61.46)
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Bilateral renal agenesis/hypoplasia No Yes 67:4737 Reference Not calculated
No No 17:671 2.38 (1.25–4.51)
Yes Yes 4:27 12.24 (3.94–38.07)
Yes No 1:2 Not calculated
Any limb deficiency No Yes 500:4737 Reference 9.86 (–17.09 
to 36.81)
No No 76:671 1.00 (0.73–1.37)
Yes Yes 15:27 4.87 (2.44–9.72)
Yes No 3:2 14.73 (2.39–90.85)
    Longitudinal limb deficiency No Yes 188:4737 Reference 18.48 (–31.43 
to 68.40)
No No 25:671 0.94 (0.57–1.56)
Yes Yes 7:27 6.37 (2.52–16.09)
Yes No 2:2 24.79 (3.34–184.23)
    Transverse deficiency limb No Yes 289:4737 Reference Not calculated
No No 48:671 1.04 (0.69–1.55)
Yes Yes 4:27 2.43 (0.83–7.15)
Yes No 0:2 Not calculated
Craniosynostosis No Yes 551:4737 Reference Not calculated
No No 52:671 0.98 (0.70–1.37)
Yes Yes 5:27 1.57 (0.59–4.21)
Yes No 0:2 Not calculated
Diaphragmatic hernia No Yes 355:4737 Reference 4.34 (–10.83 
to 19.50)
No No 45:671 0.86 (0.57–1.29)
Yes Yes 5:27 2.00 (0.69–5.86)
Yes No 1:2 6.20 (0.55–70.06)
Omphalocele No Yes 194:4737 Reference Not calculated
No No 26:671 1.09 (0.66–1.79)
Yes Yes 4:27 2.77 (0.93–8.28)
Yes No 0:2 Not calculated
Gastroschisis No Yes 496:4737 Reference Not calculated
No No 99:671 0.93 (0.69–1.25)
Yes Yes 1:27 0.41 (0.05–3.49)
Yes No 0:2 Not calculated
Sacral agenesis No Yes 23:4737 Reference 98.41 (–
314.14 to 
510.96)
No No 3:671 1.56 (0.41–5.96)
Yes Yes 9:27 82.35 (26.22–258.65)
Yes No 2:2 181.32 (18.16–1810.96)
CI, confidence interval.
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Correa. Lack of folic acid supplements and diabetes mellitus–associated birth defects. Am J Obstet Gynecol 2012.
a
For maternal diabetes mellitus: Yes = preexisting diabetes mellitus; No = no diabetes mellitus of any type
b
For use of vitamins: Yes = any use from the period of 1 month before pregnancy through the third month of pregnancy of a vitamin or supplement 
that contains folic acid; No = no use during the month before conception and the first 3 months of pregnancy of a vitamin or supplement that 
contains folic acid
c
Adjusted for maternal age, race, and ethnicity, entry into prenatal care, prepregnancy body mass index, parity, and household income
d
Note different number of control infants for oral clefts because of limited ascertainment in Utah and different number of control infants for 
hypospadias because of restriction to male infants.
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